Now showing items 1-3 of 3

    • Leschek, Ellen Werber; Rose, Susan R.; Yanovski, Jack A.; Conley, Mary; Quigley, Charmian A.; Chipman, John J.; Crowe, Brenda J.; Ross, Judith L.; Cassorla Goluboff, Fernando; Blum, Werner F.; Cutler, Gordon B.; Baron, Jeffrey (2004)
      GH is often used to treat children with idiopathic short stature despite the lack of definitive, long-term studies of efficacy. We performed a randomized, double-blind, placebo-controlled trial to determine the effect of ...
    • Ross, Judith L.; Sandberg, David E.; Rose, Susan R.; Leschek, Ellen Werber; Baron, Jeffrey; Chipman, John J.; Cassorla Goluboff, Fernando; Quigley, Charmian A.; Crowe, Brenda J.; Roberts, Kristen; Cutler, Gordon B., Jr. (2004)
      The influence of short stature on psychological adaptation in childhood and adolescence is controversial. GH is currently used to treat children with idiopathic short stature (ISS, also known as non-GH-deficient short ...
    • Quigley, Charmian A.; Gill, Anne M.; Crowe, Brenda J.; Robling, Kristen; Chipman, John J.; Rose, Susan R.; Ross, Judith L.; Cassorla Goluboff, Fernando; Wolka, Anne M.; Wit, Jan M.; Rekers-Mombarg, Lyset T.M.; Cutler, Gordon B., Jr. (ENDOCRINE SOC., 2005-09)
      Context: Recombinant human GH was approved by the United States Food and Drug Administration in 2003 for the treatment of idiopathic short stature (ISS). However, to date, the safety of GH in this patient population has ...